FTC backs rule change that could expose anticompetitive drug patent deals

US antitrust regulators have put their support behind a proposed rule change that would require pharmaceutical companies to file all "pre-institution" patent settlements with the Patent and Trademark Office (USPTO). These are the settlement agreements that are reached before the USPTO's Patent Trial and Appeal Board (PTAB) has decided whether to institute a case review.